190 related articles for article (PubMed ID: 16916720)
1. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays?
Selvarajan S; Tan SY; Sii LH; Tan PH
Pathology; 2006 Aug; 38(4):316-20. PubMed ID: 16916720
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
Graham AD; Faratian D; Rae F; Thomas JS
Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
[TBL] [Abstract][Full Text] [Related]
3. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting.
Hanna WM; Kahn HJ; Pienkowska M; Blondal J; Seth A; Marks A
Mod Pathol; 2001 Jul; 14(7):677-85. PubMed ID: 11455000
[TBL] [Abstract][Full Text] [Related]
4. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer.
Zhang D; Salto-Tellez M; Putti TC; Do E; Koay ES
Mod Pathol; 2003 Jan; 16(1):79-84. PubMed ID: 12527717
[TBL] [Abstract][Full Text] [Related]
5. Multiplexed tandem polymerase chain reaction identifies strong expression of oestrogen receptor and Her-2 from single, formalin-fixed, paraffin-embedded breast cancer sections.
Thompson EW; Warton K; Blick T; Wafai R; Hill P; Stanley K
Pathology; 2010 Feb; 42(2):165-72. PubMed ID: 20085519
[TBL] [Abstract][Full Text] [Related]
6. Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service.
Faratian D; Graham A; Rae F; Thomas J
Histopathology; 2009 Mar; 54(4):428-32. PubMed ID: 19309394
[TBL] [Abstract][Full Text] [Related]
7. Loss of antigenicity in stored sections of breast cancer tissue microarrays.
Fergenbaum JH; Garcia-Closas M; Hewitt SM; Lissowska J; Sakoda LC; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):667-72. PubMed ID: 15066936
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.
Vang R; Cooley LD; Harrison WR; Reese T; Abrams J
Am J Clin Pathol; 2000 May; 113(5):669-74. PubMed ID: 10800399
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu analysis in breast cancer bone metastases.
Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
[TBL] [Abstract][Full Text] [Related]
10. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
Erdogan S; Ergin M; Tuncer I
Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
[TBL] [Abstract][Full Text] [Related]
11. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
Benöhr P; Henkel V; Speer R; Vogel U; Sotlar K; Aydeniz B; Reiser A; Neubauer H; Tabiti K; Wallwiener D; Clare SE; Kurek R
Anticancer Res; 2005; 25(3B):1895-900. PubMed ID: 16158923
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K
Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
Bhargava R; Lal P; Chen B
Diagn Mol Pathol; 2004 Dec; 13(4):213-6. PubMed ID: 15538111
[TBL] [Abstract][Full Text] [Related]
15. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.
Purnomosari D; Aryandono T; Setiaji K; Nugraha SB; Pals G; van Diest PJ
Biotech Histochem; 2006; 81(2-3):79-85. PubMed ID: 16908432
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Shin SJ; Hyjek E; Early E; Knowles DM
Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
[TBL] [Abstract][Full Text] [Related]
17. [Measurement of HER-2/neu in breast cancer: which methodologic approach?].
Orvieto E; Dei Tos AP
Pathologica; 2001 Jun; 93(3):183-8. PubMed ID: 11433610
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.
Seth RM; Burger AM; Kahn HJ
Anticancer Res; 2006; 26(2A):927-31. PubMed ID: 16619488
[TBL] [Abstract][Full Text] [Related]
19. HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens.
Lesnikova I; Lidang M; Hamilton-Dutoit S; Koch J
APMIS; 2009 Oct; 117(10):737-45. PubMed ID: 19775342
[TBL] [Abstract][Full Text] [Related]
20. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
